IL313835A - Bicyclic triazine derivatives for the treatment of cancer - Google Patents
Bicyclic triazine derivatives for the treatment of cancerInfo
- Publication number
- IL313835A IL313835A IL313835A IL31383524A IL313835A IL 313835 A IL313835 A IL 313835A IL 313835 A IL313835 A IL 313835A IL 31383524 A IL31383524 A IL 31383524A IL 313835 A IL313835 A IL 313835A
- Authority
- IL
- Israel
- Prior art keywords
- bicyclic
- triazine
- history
- cancer treatment
- cancer
- Prior art date
Links
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22150829 | 2022-01-11 | ||
| PCT/EP2023/050208 WO2023135057A1 (en) | 2022-01-11 | 2023-01-06 | Bicyclic triazine derivatives for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL313835A true IL313835A (en) | 2024-08-01 |
Family
ID=79927598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313835A IL313835A (en) | 2022-01-11 | 2023-01-06 | Bicyclic triazine derivatives for the treatment of cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250066370A1 (https=) |
| EP (1) | EP4463458A1 (https=) |
| JP (1) | JP2025502240A (https=) |
| KR (1) | KR20240134962A (https=) |
| CN (1) | CN118541372A (https=) |
| AU (1) | AU2023207765A1 (https=) |
| CA (1) | CA3246440A1 (https=) |
| IL (1) | IL313835A (https=) |
| WO (1) | WO2023135057A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021176045A1 (en) * | 2020-03-06 | 2021-09-10 | Bayer Aktiengesellschaft | Imidazotriazines acting on cancer via inhibition of cdk12 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011529072A (ja) | 2008-07-24 | 2011-12-01 | セラヴァンス， インコーポレーテッド | 二重作用血圧降下薬 |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| TW202146416A (zh) | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| WO2021176045A1 (en) | 2020-03-06 | 2021-09-10 | Bayer Aktiengesellschaft | Imidazotriazines acting on cancer via inhibition of cdk12 |
| WO2021176049A1 (en) | 2020-03-06 | 2021-09-10 | Bayer Aktiengesellschaft | Pyrazolopyrazines acting on cancers via inhibition of cdk12 |
-
2023
- 2023-01-06 CN CN202380016568.XA patent/CN118541372A/zh active Pending
- 2023-01-06 WO PCT/EP2023/050208 patent/WO2023135057A1/en not_active Ceased
- 2023-01-06 KR KR1020247026963A patent/KR20240134962A/ko active Pending
- 2023-01-06 JP JP2024541916A patent/JP2025502240A/ja active Pending
- 2023-01-06 EP EP23702959.0A patent/EP4463458A1/en active Pending
- 2023-01-06 IL IL313835A patent/IL313835A/en unknown
- 2023-01-06 US US18/728,291 patent/US20250066370A1/en active Pending
- 2023-01-06 AU AU2023207765A patent/AU2023207765A1/en active Pending
- 2023-01-06 CA CA3246440A patent/CA3246440A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240134962A (ko) | 2024-09-10 |
| WO2023135057A1 (en) | 2023-07-20 |
| EP4463458A1 (en) | 2024-11-20 |
| CN118541372A (zh) | 2024-08-23 |
| CA3246440A1 (en) | 2023-07-20 |
| JP2025502240A (ja) | 2025-01-24 |
| AU2023207765A1 (en) | 2024-07-04 |
| US20250066370A1 (en) | 2025-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4096717T3 (da) | Behandling af cancer | |
| SI3986897T1 (sl) | Inhibitor EGFR za zdravljenje raka | |
| DK3956033T3 (da) | Bicykliske forbindelser | |
| EP3743117C0 (en) | DECONTAMINATION METHOD BY PHOTOBIOMODULATION | |
| HUE050155T2 (hu) | 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére | |
| IL314136A (en) | Imidazole macrocycles for the treatment of autoimmune disease | |
| EP4493175A4 (en) | MIRDAMETINIB TREATMENT | |
| IL287904A (en) | Combination treatment of arthritic disease | |
| IL304595A (en) | Bicyclic tetrahydrozepine derivatives for cancer treatment | |
| EP4205812C0 (en) | FULLY SPHERICAL RADIOTHERAPY SYSTEM | |
| EP4232450A4 (en) | BICYCLIC COMPOUNDS | |
| EP4178042A4 (en) | CONNECTOR | |
| PT3952858T (pt) | Método de tratamento de tumores | |
| EP4102649A4 (en) | CONNECTOR | |
| IL310870A (en) | Quinazoline compounds for treatment of disease | |
| EP4440623A4 (en) | Polytherapy for the treatment of cancer | |
| IL288408A (en) | Methods of treating urinary system cancers | |
| EP4415766A4 (en) | UV RADIATION SOURCE ASSEMBLY | |
| IL313835A (en) | Bicyclic triazine derivatives for the treatment of cancer | |
| EP4271392A4 (en) | MATRIX-DIRECTED IMMUNOMODULATION FOR CANCER THERAPY | |
| IL289201A (en) | Compounds for the treatment of cancer | |
| EP4401721A4 (en) | CANCER TREATMENT | |
| EP3952987C0 (en) | RADIOTHERAPY OPTIMIZATION SYSTEM | |
| EP4331663A4 (en) | LIGHT IRRADIATION SYSTEM | |
| IL305780A (en) | Cancer treatment methods |